STOCK TITAN

GBS Inc. to Present at the H.C. Wainwright Global Investment Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

GBS Inc. (Nasdaq: GBS), a life sciences company focused on non-invasive diagnostic testing, announced participation in the H.C. Wainwright Global Investment Conference scheduled for May 23–26, 2022. Dr. Steven Boyages, interim CEO, along with the management team, will engage in virtual one-on-one meetings with investors on May 24 at 7:00 AM ET. The conference aims to showcase GBS's innovative Biosensor Platform, which is essential for monitoring diabetes. Interested participants can register via the HCW events website for further engagement.

Positive
  • None.
Negative
  • None.

NEW YORK, May 16, 2022 (GLOBE NEWSWIRE) -- GBS Inc. (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at point-of-care, today announced that, today announced that Dr. Steven Boyages, GBS’ interim CEO and Chairman of the Board, along with other management team members will participate at the H.C. Wainwright Global Investment Conference being held May 23–26, 2022 and invites investors to participate via virtual one-on-one meetings. Please see additional details below:

H.C. Wainwright Global Investment Conference (Hybrid Conference)
Date: Tuesday, May 24, 2022
Time: 7:00 AM ET
Webcast & Registration Link:
https://journey.ct.events/view/66305df8-460c-4b10-a660-6423d577f5b4

If you have interest in participating in the H.C. Wainwright Global Investment Conference, please reach out to your representative or register at the HCW events website.

About GBS Inc.
GBS Inc. is a life sciences company developing non-invasive, real-time monitoring and diagnostic tests for patients and their primary health practitioners. With the world-first Biosensor Platform, GBS Inc. is developing and launching diagnostic tests urgently needed to help people living with diabetes. For more information, please visit GBS.inc.

Company Contact:
Alex Arzeno – Vice President of IR & Communications
GBS, Inc.
Investor.Relations@gbs.inc

Investor Contact:
Tim McCarthy – Managing Director
LifeSci Advisors, LLC
Tim@LifeSciAdvisors.com


FAQ

What is GBS Inc.'s focus in the stock market?

GBS Inc. specializes in non-invasive, real-time diagnostic testing for diabetes and other conditions.

When will GBS participate in the H.C. Wainwright Global Investment Conference?

GBS will participate in the conference on May 24, 2022, at 7:00 AM ET.

Who will represent GBS at the conference?

Dr. Steven Boyages, the interim CEO, along with other management team members, will represent GBS.

How can I register for the H.C. Wainwright Global Investment Conference?

Participants can register for the conference by visiting the HCW events website.

What innovative platform is GBS Inc. developing?

GBS Inc. is developing the world-first Biosensor Platform for real-time monitoring of health conditions.

GBS

:GBS

GBS Rankings

GBS Latest News

GBS Stock Data

7.05M
13.47M
9.05%
2.79%
1.02%
Medical Devices
Healthcare
Link
United States
New York